Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| fibroblast | 10 studies | 24% ± 9% | |
| smooth muscle cell | 8 studies | 22% ± 7% | |
| myofibroblast cell | 7 studies | 19% ± 3% | |
| pericyte | 7 studies | 21% ± 5% | |
| connective tissue cell | 6 studies | 28% ± 5% | |
| epithelial cell | 6 studies | 34% ± 14% | |
| ciliated cell | 6 studies | 28% ± 8% | |
| basal cell | 5 studies | 28% ± 13% | |
| neuron | 5 studies | 33% ± 15% | |
| abnormal cell | 4 studies | 21% ± 5% | |
| pancreatic A cell | 3 studies | 29% ± 9% | |
| hematopoietic precursor cell | 3 studies | 18% ± 1% | |
| kidney loop of Henle epithelial cell | 3 studies | 22% ± 2% | |
| neural crest cell | 3 studies | 27% ± 3% | |
| progenitor cell | 3 studies | 22% ± 8% | |
| type I pneumocyte | 3 studies | 24% ± 5% | |
| retina horizontal cell | 3 studies | 32% ± 15% | |
| dendritic cell | 3 studies | 36% ± 9% | |
| oligodendrocyte precursor cell | 3 studies | 25% ± 4% | |
| goblet cell | 3 studies | 28% ± 9% | |
| B cell | 3 studies | 16% ± 1% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| brain | 100% | 2485.40 | 2642 / 2642 | 100% | 167.94 | 705 / 705 |
| thymus | 100% | 2247.29 | 653 / 653 | 100% | 173.07 | 604 / 605 |
| prostate | 100% | 2220.73 | 245 / 245 | 100% | 128.62 | 501 / 502 |
| ovary | 100% | 1895.09 | 180 / 180 | 100% | 143.52 | 429 / 430 |
| pancreas | 100% | 1196.13 | 327 / 328 | 100% | 91.33 | 178 / 178 |
| breast | 100% | 1620.59 | 459 / 459 | 100% | 134.85 | 1113 / 1118 |
| uterus | 100% | 2295.45 | 170 / 170 | 99% | 143.15 | 456 / 459 |
| stomach | 100% | 1560.66 | 359 / 359 | 99% | 68.73 | 284 / 286 |
| lung | 100% | 1596.41 | 576 / 578 | 99% | 132.64 | 1149 / 1155 |
| bladder | 100% | 2030.43 | 21 / 21 | 99% | 106.05 | 499 / 504 |
| intestine | 100% | 1855.07 | 966 / 966 | 98% | 75.79 | 519 / 527 |
| kidney | 100% | 1733.04 | 89 / 89 | 98% | 68.00 | 887 / 901 |
| skin | 100% | 1655.41 | 1808 / 1809 | 98% | 103.80 | 463 / 472 |
| esophagus | 100% | 1715.94 | 1445 / 1445 | 97% | 79.49 | 178 / 183 |
| adrenal gland | 100% | 1972.05 | 258 / 258 | 95% | 82.92 | 218 / 230 |
| liver | 100% | 986.45 | 226 / 226 | 85% | 43.35 | 344 / 406 |
| spleen | 100% | 1409.32 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 97.73 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 54.89 | 1 / 1 |
| blood vessel | 100% | 1832.91 | 1334 / 1335 | 0% | 0 | 0 / 0 |
| adipose | 100% | 1145.36 | 1200 / 1204 | 0% | 0 | 0 / 0 |
| muscle | 99% | 1072.92 | 798 / 803 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 97% | 75.02 | 28 / 29 |
| eye | 0% | 0 | 0 / 0 | 96% | 56.47 | 77 / 80 |
| heart | 95% | 1168.57 | 819 / 861 | 0% | 0 | 0 / 0 |
| peripheral blood | 27% | 285.66 | 251 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0016567 | Biological process | protein ubiquitination |
| GO_0097428 | Biological process | protein maturation by iron-sulfur cluster transfer |
| GO_2000060 | Biological process | positive regulation of ubiquitin-dependent protein catabolic process |
| GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
| GO_2000042 | Biological process | negative regulation of double-strand break repair via homologous recombination |
| GO_0005634 | Cellular component | nucleus |
| GO_0005515 | Molecular function | protein binding |
| Gene name | MAGEF1 |
| Protein name | Melanoma-associated antigen F1 (MAGE-F1) (MAGE-F1 antigen) |
| Synonyms | |
| Description | FUNCTION: Enhances ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin ligases. Proposed to act through recruitment and/or stabilization of the E2 ubiquitin-conjugating enzyme at the E3:substrate complex. MAGEF1-NSMCE1 ubiquitin ligase complex promotes proteasomal degradation of MMS19, a key component of the cytosolic iron-sulfur protein assembly (CIA) machinery. Down-regulation of MMS19 impairs the activity of several DNA repair and metabolism enzymes such as ERCC2/XPD, FANCJ, RTEL1 and POLD1 that require iron-sulfur clusters as cofactors. May negatively regulate genome integrity by inhibiting homologous recombination-mediated double-strand break DNA repair . . |
| Accessions | Q9HAY2 ENST00000317897.5 |